A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

This is a randomized (assignment of study drug by chance), double-blind (neither the
participant or study staff will know the identity of study drugs), placebo- (inactive
substance identical in appearance to study drug) and active-comparator-controlled (use of an
approved drug to compare with study drug) study of guselkumab. The active comparator study
drug is adalimumab, an approved drug for the treatment of moderate to severe plaque
psoriasis. Participants who satisfy all inclusion and exclusion criteria will be randomly
assigned in a 2:1:1 ratio to one of three treatment groups (arms): Group I (guselkumab 100 mg
dose regimen), Group II (placebo then crossover to guselkumab at Week 16), or Group III
(adalimumab at standard psoriasis dosing). From Week 28 up to Week 76, treatment for all
participants will be based on their level of response. All participants will receive
guselkumab every 8 weeks from Week 76 through Week 252 with a final safety follow-up visit at
Week 264 (open label treatment period). The end of the study is defined as the time the last
participant completes the Week 264 visit. The total duration of the study will be
approximately 268 weeks (includes a 4-week screening period). Participants will be monitored
for safety throughout the study.

Inclusion Criteria:

- Have a diagnosis of plaque-type psoriasis (with or without psoriatic arthritis) at
least 6 months before the first administration of study agent

- Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at
Screening and at Baseline

- Have an Investigator's Global Assessment (IGA) score >=3 at Screening and at Baseline

- Have an involved body surface area (BSA) >=10 percent (%) at Screening and at Baseline

- Must be a candidate for either systemic therapy or phototherapy for psoriasis

Exclusion Criteria:

- Participants with nonplaque forms of psoriasis (for example, erythrodermic, guttate,
or pustular) or with current drug-induced psoriasis (for example, a new onset of
psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel
blockers, or lithium)

- Participants who have ever received guselkumab or adalimumab

- History or current signs or symptoms of severe, progressive, or uncontrolled renal,
hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,
hematologic, rheumatologic, psychiatric, or metabolic disturbances

- Has any condition that, in the opinion of the investigator, would make participation
not be in the best interest (for example, compromise the well-being) of the
participant or that could prevent, limit, or confound the protocol-specified
assessments

- Is pregnant, nursing, or planning a pregnancy (both men and women) within 5 months
following the last administration of study drug